Challenges for In Vivo Delivery of Genetic Medicines: Despite recent FDA approvals and the early success of genetic medicines, significant challenges remain that we believe can be addressed by our complimentary platforms of high-capacity evolved vectors that exhibit tissue-specific tropism.
AAV vectors have a limited payload carry capacity of ~4.8 kB. This means AAVs can’t deliver: large human transgenes (such as Dystrophin or CFTR), gene editing (CRISPR), base editing, or prime editing constructs, multiple transgenes, and larger promoter and regulatory elements including “off switches.”
Challenges with Oncolytic Immunotherapies include local-regional efficacy only, inefficient intravenous delivery to tumors, repeat dosing, limited ability to turn cold tumors hot, and lack of tumor-specific combination therapies (e.g. checkpoint inhibitors).
ReIGNITE’s proprietary high-capacity viral vector discovery platform uses Directed Evolution to generate proprietary oncolytic immunotherapies and gene therapies.
The vaccinia virus can infect a wide variety of cell types, making it a versatile tool for targeting different kinds of cancer. Its ability to infect and replicate within a broad range of host cells enhances its applicability as a vector for cancer therapy across diverse cancer types.
Adenoviruses are capable of carrying and delivering large genetic payloads (up to 36 kB). This allows for the incorporation of multiple therapeutic genes, including those that can boost the immune response or make cancer cells more susceptible to treatment, enhancing the overall efficacy of the therapy.
ReIGNITE's oncolytic immunotherapy program uses a proprietary vaccinia virus construct, administered intravenously, to target solid tumors.
Capability to employ a variety of routes of administration for targeted delivery and biodistribution, including intravenous, inhaled, subcutaneous, intramuscular, and intrathecal
ReIGNITE's lead program using a vaccinia virus construct is entering IND-enabling studies.
Our adenovirus gene therapy platform is in development for the precise delivery of large transgenes (up to 36 kB) for genetic disorders.
ReIGNITE is also expanding and diversifying its pipeline of therapeutics across hematologic malignancies, solid tumors, and monogenic genetic diseases that require the delivery of large or multiple transgenes.
